HK1206387A1 - Organic compositions to treat kras-related diseases - Google Patents
Organic compositions to treat kras-related diseases Download PDFInfo
- Publication number
- HK1206387A1 HK1206387A1 HK15106884.9A HK15106884A HK1206387A1 HK 1206387 A1 HK1206387 A1 HK 1206387A1 HK 15106884 A HK15106884 A HK 15106884A HK 1206387 A1 HK1206387 A1 HK 1206387A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- strand
- rnai agent
- kras
- nucleotides
- modified
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641588P | 2012-05-02 | 2012-05-02 | |
| US61/641,588 | 2012-05-02 | ||
| PCT/US2013/038847 WO2013166004A2 (en) | 2012-05-02 | 2013-04-30 | Organic compositions to treat kras-related diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1206387A1 true HK1206387A1 (en) | 2016-01-08 |
Family
ID=48366565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15106884.9A HK1206387A1 (en) | 2012-05-02 | 2013-04-30 | Organic compositions to treat kras-related diseases |
Country Status (12)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201620525A (zh) * | 2014-03-14 | 2016-06-16 | 波士頓生醫公司 | 使ｋ－ｒａｓ靜默之非對稱干擾ｒｎａ組成物及其使用方法 |
| CN106687121A (zh) | 2014-05-14 | 2017-05-17 | 亚历克斯利维斯兹奇管理和控股有限公司 | 改善的聚乙烯亚胺聚乙二醇载体 |
| US11180759B2 (en) * | 2016-01-19 | 2021-11-23 | The University Of North Carolina At Chapel Hill | Methods and compositions using RNA interference and antisense oligonucleotides for inhibition of KRAS |
| MA45328A (fr) | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Compositions acide nucléique-polypeptide et utilisations de celles-ci |
| MA45470A (fr) * | 2016-04-01 | 2019-02-06 | Avidity Biosciences Llc | Acides nucléiques kras et leurs utilisations |
| KR102543645B1 (ko) * | 2016-07-20 | 2023-06-16 | 주식회사 지씨지놈 | 유전성 발달장애 진단용 조성물 및 이의 용도 |
| IL319835A (en) | 2017-12-06 | 2025-05-01 | Avidity Biosciences Inc | Compositions and methods for treating muscular dystrophy and myotonic dystrophy |
| AU2020287343A1 (en) * | 2019-06-05 | 2021-12-09 | Southern Research Institute | Thiarabine- and thiarabine prodrug-based treatments |
| US12146139B2 (en) * | 2019-11-14 | 2024-11-19 | The Board Of Regents Of The University Of Oklahoma | Oligonucleotide interference treatments of prostate cancer |
| KR20220156867A (ko) | 2020-03-19 | 2022-11-28 | 어비디티 바이오사이언시스 인크. | 안면견갑상완 근이영양증의 치료용 조성물 및 방법 |
| JP2023521383A (ja) * | 2020-04-07 | 2023-05-24 | ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | Ｋｒａｓの阻害のためのｒｎａ干渉およびアンチセンスオリゴヌクレオチドを使用する方法および組成物 |
| EP4395901A4 (en) * | 2021-09-02 | 2025-10-01 | Molecular Axiom Llc | COMPOSITIONS AND METHODS FOR MODULATING KRAS EXPRESSION |
| EP4401792A4 (en) | 2021-09-16 | 2025-12-03 | Avidity Biosciences Inc | COMPOSITIONS AND METHODS OF TREATMENT OF FACIO-SCAPULO-HUMERAL MUSCULAR DYSTROPHY |
| EP4652279A2 (en) * | 2023-01-18 | 2025-11-26 | Molecular Axiom, LLC | Compositions for modulating kras expression and uses thereof |
| AU2024225428A1 (en) * | 2023-02-22 | 2025-08-28 | Altamira Therapeutics Ag | Compositions and methods for kras inhibition for the treatment of disease |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5030453A (en) | 1983-03-24 | 1991-07-09 | The Liposome Company, Inc. | Stable plurilamellar vesicles |
| US6977244B2 (en) | 1996-10-04 | 2005-12-20 | Board Of Regents, The University Of Texas Systems | Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| US5891467A (en) | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| IL151781A0 (en) | 2000-03-16 | 2003-04-10 | Genetica Inc | Methods and compositions for rna interference |
| US6680068B2 (en) | 2000-07-06 | 2004-01-20 | The General Hospital Corporation | Drug delivery formulations and targeting |
| WO2002100435A1 (en) | 2001-06-11 | 2002-12-19 | Centre Hospitalier Universitaire De Montreal | Compositions and methods for enhancing nucleic acid transfer into cells |
| ATE468861T1 (de) | 2001-08-16 | 2010-06-15 | Univ Pennsylvania | Synthese und verwendung von reagenzien für die verbesserte dna-lipofektion und/oder prodrug- und arzneimitteltherapien mit langsamer freisetzung |
| ES2354607T3 (es) | 2002-06-28 | 2011-03-16 | Protiva Biotherapeutics Inc. | Procedimiento y aparato para producir liposomas. |
| CA2500468A1 (en) | 2002-09-28 | 2004-04-08 | Massachussets Institute Of Technology | Influenza therapeutic |
| US8090542B2 (en) * | 2002-11-14 | 2012-01-03 | Dharmacon Inc. | Functional and hyperfunctional siRNA |
| EP1585756B1 (en) | 2002-11-26 | 2010-04-21 | University of Massachusetts | Delivery of sirnas |
| US20040208921A1 (en) | 2003-01-14 | 2004-10-21 | Ho Rodney J. Y. | Lipid-drug formulations and methods for targeted delivery of lipid-drug complexes to lymphoid tissues |
| JP4951338B2 (ja) | 2003-07-16 | 2012-06-13 | プロチバ バイオセラピューティクス インコーポレイティッド | 脂質に封入された干渉ｒｎａ |
| WO2005021749A1 (en) | 2003-08-28 | 2005-03-10 | Novartis Ag | Interfering rna duplex having blunt-ends and 3’-modifications |
| EP1675949A2 (en) * | 2003-10-23 | 2006-07-05 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF NOGO AND NOGO RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| EP1714970A1 (en) * | 2005-04-22 | 2006-10-25 | Universität des Saarlandes | Use of inhibitors of RNAse A-family enzymes for stabilizing oligonucleotides having RNA interfering activity |
| CA2628300C (en) | 2005-11-02 | 2018-04-17 | Protiva Biotherapeutics, Inc. | Modified sirna molecules and uses thereof |
| EP2002004B1 (en) | 2006-03-23 | 2015-10-14 | Roche Innovation Center Copenhagen A/S | Small internally segmented interfering rna |
| GB0608838D0 (en) | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
| EP2081949B1 (en) * | 2006-09-22 | 2014-12-10 | GE Healthcare Dharmacon, Inc. | Tripartite oligonucleotide complexes and methods for gene silencing by rna interference |
| EP2121925A2 (en) * | 2007-03-02 | 2009-11-25 | MDRNA, Inc. | Nucleic acid compounds for inhibiting ras gene expression and uses thereof |
| NZ580712A (en) | 2007-05-22 | 2011-12-22 | Marina Biotech Inc | Hydroxymethyl substituted rna oligonucleotides and rna complexes containing acyclic monomers |
| EP2190995A2 (en) * | 2007-09-18 | 2010-06-02 | Intradigm Corporation | Compositions comprising k-ras sirna and methods of use |
| WO2009062199A1 (en) * | 2007-11-09 | 2009-05-14 | Fox Chase Cancer Center | EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS |
| EP2238251B1 (en) | 2007-12-27 | 2015-02-11 | Protiva Biotherapeutics Inc. | Silencing of polo-like kinase expression using interfering rna |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| WO2010006237A2 (en) * | 2008-07-11 | 2010-01-14 | Alnylam Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides non-nucleosidic phosphorothiotes as delivery agents for irna agents |
| WO2010115202A2 (en) * | 2009-04-03 | 2010-10-07 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of kras by blunt ended double-stranded rna |
| EP3199165B1 (en) * | 2009-04-03 | 2022-06-08 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of kras by asymmetric double-stranded rna |
| AU2010334911A1 (en) | 2009-12-23 | 2012-07-12 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| US20130116302A1 (en) * | 2010-03-12 | 2013-05-09 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Pharmaceutical composition for the treatment of chlamydial infection |
-
2013
- 2013-04-30 US US14/397,815 patent/US20150238515A1/en not_active Abandoned
- 2013-04-30 EP EP13721578.6A patent/EP2844757A2/en not_active Withdrawn
- 2013-04-30 AU AU2013256471A patent/AU2013256471A1/en not_active Abandoned
- 2013-04-30 CA CA3173610A patent/CA3173610A1/en active Pending
- 2013-04-30 CA CA2872304A patent/CA2872304C/en active Active
- 2013-04-30 BR BR112014027337A patent/BR112014027337A2/pt not_active IP Right Cessation
- 2013-04-30 EP EP17187348.2A patent/EP3272868A1/en not_active Ceased
- 2013-04-30 WO PCT/US2013/038847 patent/WO2013166004A2/en not_active Ceased
- 2013-04-30 EA EA201492004A patent/EA201492004A1/ru unknown
- 2013-04-30 CN CN201811456141.9A patent/CN109481455A/zh active Pending
- 2013-04-30 CN CN201380035099.2A patent/CN104583406A/zh active Pending
- 2013-04-30 HK HK15106884.9A patent/HK1206387A1/xx unknown
- 2013-04-30 JP JP2015510380A patent/JP2015517466A/ja active Pending
- 2013-04-30 MX MX2014013367A patent/MX2014013367A/es unknown
- 2013-04-30 EP EP20178501.1A patent/EP3736333A1/en active Pending
- 2013-04-30 KR KR20147033421A patent/KR20150004414A/ko not_active Withdrawn
-
2016
- 2016-07-11 AU AU2016204832A patent/AU2016204832A1/en not_active Abandoned
- 2016-09-07 US US15/258,042 patent/US20180153919A1/en not_active Abandoned
-
2017
- 2017-11-14 AU AU2017261481A patent/AU2017261481A1/en not_active Abandoned
-
2020
- 2020-01-14 AU AU2020200247A patent/AU2020200247A1/en not_active Abandoned
-
2022
- 2022-05-04 AU AU2022202991A patent/AU2022202991A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014027337A2 (pt) | 2017-07-18 |
| MX2014013367A (es) | 2014-12-08 |
| WO2013166004A3 (en) | 2014-01-03 |
| CA2872304C (en) | 2022-12-06 |
| US20150238515A1 (en) | 2015-08-27 |
| CN109481455A (zh) | 2019-03-19 |
| CN104583406A (zh) | 2015-04-29 |
| CA2872304A1 (en) | 2013-11-07 |
| AU2016204832A1 (en) | 2016-07-28 |
| AU2022202991A1 (en) | 2022-05-26 |
| EP2844757A2 (en) | 2015-03-11 |
| AU2020200247A1 (en) | 2020-02-06 |
| US20180153919A1 (en) | 2018-06-07 |
| AU2017261481A1 (en) | 2017-11-30 |
| EP3736333A1 (en) | 2020-11-11 |
| EA201492004A1 (ru) | 2015-08-31 |
| KR20150004414A (ko) | 2015-01-12 |
| JP2015517466A (ja) | 2015-06-22 |
| WO2013166004A2 (en) | 2013-11-07 |
| EP3272868A1 (en) | 2018-01-24 |
| AU2013256471A1 (en) | 2014-11-13 |
| CA3173610A1 (en) | 2013-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1206387A1 (en) | Organic compositions to treat kras-related diseases | |
| KR101718297B1 (ko) | Ｈｓｆ1-관련 질환을 치료하기 위한 유기 조성물 | |
| JP2021521796A (ja) | 高コレステロール血症及び関連状態を治療するための、ｐｃｓｋ９を標的とするオリゴヌクレオチド | |
| US11261444B2 (en) | Organic compositions to treat EPAS1-related diseases | |
| EP3061824B1 (en) | Organic compositions to treat beta-enac-related diseases | |
| CN103930547A (zh) | 用于治疗hsf1相关疾病的有机组合物 | |
| KR20200023427A (ko) | Hmgb1 발현을 억제하기 위한 조성물 및 방법 | |
| AU2011244335A1 (en) | Organic compositions to treat Beta-ENaC-related diseases | |
| HK1205758A1 (en) | Rnai agents to treat beta-catenin related diseases | |
| WO2021209608A1 (en) | Medical methods and medical uses | |
| HK1172926A (en) | Organic compositions to treat hsf1-related diseases |